• Morphotek Inc., of Exton, Pa., a subsidiary of Eisai Inc., began a Phase II trial of MORAb-004 for colorectal cancer. The randomized, double-blind, placebo-controlled trial will evaluate safety and efficacy of single-agent MORAb-004 with supportive care for progression-free survival in patients with chemo-refractory metastatic colorectal cancer. Secondary endpoints include overall survival and identification of efficacy biomarkers.